 |
|
CLINICAL TRIALS
SUB-TOPICS |
|
| AMD |
|
| Bevasiranib |
|
| VEGF |
| | |
| |
 |
| |
| |
| | |
Bevasiranib or Cand5
Our most advanced therapeutic compound, known as Cand5 or bevasiranib, is being studied in Phase III clinical trials. Bevasiranib is an siRNA that works to silence the genes that promote the overgrowth of blood vessels that lead to vision loss in Wet AMD. Bevasiranib is a synthetic double-stranded RNA (dsRNA) oligonucleotide that selectively inhibits the production of all isoforms of VEGF by efficiently and effectively halting the production of VEGF on the mRNA level. VEGF is a protein that has been shown to be the central stimulus in the development of ocular neovascularization. Bevasiranib is administered locally to the eye via an intravitreal injection.
Significant scientific evidence suggests that the presence in the eye of elevated levels of VEGF plays an important role in causing abnormal blood vessel growth and blood vessel leakage. Bevasiranib addresses the underlying source of VEGF production, rather than neutralizing existing VEGF that has already been active in the disease pathogenesis.
Based on our bevasiranib Phase II clinical trial results, bevasiranib could be used as a monotherapy or in combination
| |
| | |  | | | | |
| |
| |
|
| OPKO currently enrolling Phase 3 trial with Bevasiranib in wet AMD. |
| full details |
| |
|
|
